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Abstract
Aim: This study aimed to longitudinally analyze Quality of Life and its association with physical and psychosocial factors of patients with
colorectal cancer.
Method: Fifty-one outpatients undergoing treatment for colorectal cancer were elected for convenience and were evaluated twice during
their treatment. Evaluations were performed for Quality of Life, as well as socio-demographic, diagnostic and therapeutic variables.
Afterwards, descriptive and inferential statistical analysis were performed, establishing the appropriate comparisons.
Results: The results identified a characteristic profile with a relatively homogeneous distribution: 51% were men with an average age of
60.1 years old (SD = 9.3 years) at the baseline. In general, concerning psychosocial aspects, there was a higher Quality of Life than other
studies with the same population, in addition to a significant improvement over time in all subscales of performance and symptoms.
Furthermore, it was evidenced that the physical aspects considerably influenced the self-report of the Quality of Life.
Conclusion: The recognition of the interferences that physical aspects pose to Quality of Life, should permeate the practices of teams
involved in the care of these patients.
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Resumo
Objetivo: Este estudo teve como objetivo analisar longitudinalmente a qualidade de vida e sua associação com fatores físicos e
psicossociais, de pacientes com cancro colorretal.
Método: Cinquenta e um pacientes externos submetidos a tratamento para cancro colorretal foram selecionados por conveniência e
avaliados duas vezes durante o tratamento. As avaliações foram realizadas para Qualidade de Vida, bem como variáveis
sociodemográficas, diagnósticas e terapêuticas. Posteriormente, foram realizadas análises estatísticas descritivas e inferenciais,
estabelecendo as comparações apropriadas.
Resultados: Os resultados identificaram um perfil característico com uma distribuição relativamente homogénea: 51% eram homens com
idade média de 60.1 anos (DP = 9,3 anos) na amostra de base. Em geral, quanto aos aspetos psicossociais, foi apresentada maior
Qualidade de Vida do que noutros estudos com a mesma população, para além de uma melhoria significativa ao longo do tempo em todas
as subescalas de desempenho e sintomas. Além disso, constatou-se que os aspetos físicos influenciaram consideravelmente o autorrelato
da Qualidade de Vida.
Conclusão: O reconhecimento das interferências que aspetos físicos colocam sobre a Qualidade de Vida, deve permear as práticas das
equipas envolvidas no cuidado desses pacientes.
Palavras-Chave: qualidade de vida, cancro colorretal, quimioterapia
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It was estimated that in 2015, more than 579,000 new cancer cases would occur in Brazil. Among these cases,
approximately 14,180 will be of colon and rectal cancer (colorectal cancer) in men and 15,960 in women. The
mortality rates of colon and rectal cancer in 100,000 inhabitants found in the period from 2010 to 2011 were:
9.05 and 7.11 in Brazil; 10.60 and 8.16 in the world and 12.40 and 12.49 in the state of Rio Grande do Sul (men
and women respectively) (Instituto Nacional do Câncer José Alencar Gomes da Silva [INCA], 2014).
Colorectal cancer presents features that may include surgical intervention, chemotherapy, radiotherapy and in
some cases the use of monoclonal antibodies (concomitant to chemotherapy), these treatments can occur sep-
arately, jointly or continuously (Sociedade Brasileira de Oncologia Clínica [SBOC], 2011).
Quality of Life is a definition with especially important multidimensional foundations. When we treat patients
with advanced cancer this becomes the goal of the treatment, both its maintenance and its improvement
(Wong, Lam, Poon, & Kwong, 2013). Factors such as chemotherapy, radiotherapy and spiritual well-being can
potentially interfere, which should be considered when the focus are on the most effective palliative care (Wong
et al., 2013). In addition, Quality of Life is an indicator of mortality and survival, as well as an indicator of im-
provement in certain functions of the patient's life, in addition to making it possible to determine the efficacy of
treatments (Chou, Stewart, Wild, & Bloom, 2012; Efficace, Bottomley, Vandvoorden, & Blazeby, 2004; Meeske
et al., 2007).
In this sense, the identification of which domains of Quality of Life are affected in the patients with colorectal
cancer has evidenced that the Quality of Life scores are in general satisfactory (Nicolussi & Sawada, 2009).
There are, however, indicative of significant interferences in the domains and subscales: emotional perform-
ance, pain symptoms, insomnia, fatigue and financial difficulties (Nicolussi & Sawada, 2009). Studies on this
subject also shows bottom inferior female performance where the members reached lower scores of cognitive,
emotional performance and in symptoms such as: pain, insomnia and fatigue, constipation and loss of appetite
(Nicolussi & Sawada, 2009).
From these evaluation subscales we can see a great exception in palliative care patients whose condition has a
negative impact on Quality of Life (Färkkilä et al., 2013). We should also highlight that patients in radiotherapy
had higher pain scores. Finally, the asymptomatic ones were those that obtained better global Quality of Life
scores (Färkkilä et al., 2013).
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In Malaysia, a study with patients in stages III and IV of colorectal cancer who proposed to evaluate Quality of
Life using the C-30 instrument of the European Organization for Treatment of Cancer Research (EORTC) iden-
tified that emotional, cognitive and social performance deteriorates along with the disease progression (Wan
Puteh et al., 2013). In addition, patients with advanced disease show more pain, dyspnea, diarrhea, and finan-
cial difficulties than the patients without advanced disease (Wan Puteh et al., 2013).
The results are similar to those found in a Chinese study, even if it is with a different instrument for measuring
Quality of Life (Wong et al., 2013). However, in the Chinese population, the identification of colorectal cancer
patients presented better performance in the mental domain than the value established for the Chinese general
population (Wong et al., 2014).
Another study on this same clinical population showed that Quality of Life in Malaysia is compared to devel-
oped countries, and highlighted a difference where the female has worse pain, fatigue and dyspnea scores
(Natrah, Ezat, Syed, Rizali, & Saperi, 2012).
In addition, the K-RAS gene when in its wild form is related to a worse Quality of Life, when compared to its
mutated form, soon its identification becomes important for the definition of oncological care behaviors (Ooki et
al., 2014; Ringash et al., 2014).
On the other hand, the performance status (PS) is a global assessment of the patient performed by the profes-
sional of their functional capacity, which directly affects biopsychosocial health in this way, making it a valuable
way of health assessment (Dajczman et al., 2008).
Thus, the objective of this study was to identify socio-demographic, psychosocial and physical factors that may
be related to Quality of Life and other clinical characteristics in patients with colorectal cancer because there
are a great number of patients who suffer severely from this type of cancer.
Method
Participants
The study sample consisted in 51 patients with colorectal cancer diagnosed and who were on antineoplastic
therapy at baseline and at follow-up. The sample was chosen for convenience. Colorectal cancer diagnosed
and who were on antineoplastic therapy at baseline and at follow-up.
The latest one performed with the survivors, who may be undergoing treatment or only under medical supervi-
sion. The baseline occurred between July 2010 and September 2011 in a private clinic, located in Porto Alegre,
Brazil.
The follow-up occurred between October 2013 and April 2014. In order to calculate the sample size, it was
used the sample calculation program of the Laboratory of Epidemiology and Statistics of the University of São
Paulo (LEE-USP), which is a program used to facilitate the process of sample size, in order to find the differ-
ence between the estimates of the means of the pre (T1) and post of the Quality of Life score.
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A standard deviation of 10.0% was considered; level of significance of 95% (α = 0.05); a sampling power of
80% (1-β) in order to detect a minimum difference of 7.8 in the functional scale variation. The result for the mini-
mum size sample test was 19 individuals at follow-up stage. It was considered as inclusion criteria: (a) to have
agreed and signed the informed consent form to participate in the study; (b) to be aged equal or greater than 18
years; (c) to have done at least the first course of antineoplastic treatment; (d) to have enough time to answer
the questionnaire; (e) not to have cognitive impairment identified at a clinical interview. The study was approved
by the Research Ethics Committee N ° 2010/068.
Measures
The participants were evaluated by a set of instruments, which included:
Medical Records
Through the analysis of Medical Records we obtained information such as staging, presence of ostomy, time of
diagnosis, K-RAS mutation, protocol of antineoplastic treatment adopted and body mass index.
Socio-Demographic Questionnaire
The instrument is used to outline a profile of the participants. In this questionnaire it will be gathered data such
as sex, schooling, marital status, date of birth, children, income, address.
C-30 Quality of Life Questionnaire
It is a scale, which evaluates Quality of Life in patients with cancer developed by the European Organization for
Research and Treatment of Cancer (EORTC). It consists of 30 items divided into performance and symptom
subscales, namely: functional subscales (which include physical, functional, emotional, cognitive, and social di-
mensions), subscales of symptoms (fatigue, nausea and vomiting, pain, dyspnea, insomnia, loss of appetite,
constipation, diarrhea, financial difficulties) and a global health Quality of Life.
The first 28 are arranged in Likert four-point scales, where 1 = not and 4 = a lot. The last two are the Likert type
of seven points, where 0 is bad and 7 is great. It was adapted and validated for the Portuguese language of
Brazil by Paiva and collaborators (2014). Adequate internal consistency with its constructs showing Cronbach's
alpha greater than 0.7 (with the exception of the cognitive subscales = 0.57, social = 0.69 and nausea and
vomiting 0.68 this results is a limitation; Aaronson et al., 1993; Fayers, Bottomley, & EORTC, 2002; Paiva et al.,
2014).
The reference values of the Quality of Life C-30 contained in the EORTC reference manual presented by Scott
et al. (2008) were adopted as a parameter only the scoring corresponding to the population with colorectal can-
cer, which are described in the Table 1.
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Table 1
EORTC’s Reference Score Values for Quality of Life C-30 Colorectal Cancer Patients
C-30 subscale M SD
Health and overall QoL 60.7 23.4
Physical Functioninga 79.2 21.1
Functional Rolea 70.4 32.8
Emotional Functioninga 68.9 24.5
Cognitive Functioninga 85.2 20.0
Social Functioninga 76.0 28.6
Fatigueb 34.7 28.4
Nausea and vomitingb 7.3 17.2
Painb 24.0 29.6
Dispyneab 17.4 26.3
Insomniab 30.5 32.6
Loss of appetiteb 19.1 30.2
Constipationb 15.8 27.9
Diarrheab 16.6 27.6
Financial difficultiesb 13.6 26.3
aOn functioning subscales high scores mean better results. bOn symptoms subscales high scores mean
worst results.
Performance Status of Eastern Cooperative Oncology Group (PS-ECOG)
Performance Status ECOG is a five-point scale widely used in clinical study and practice by the medical com-
munity and has a score ranging from 0 (totally ambulatory, without physical symptoms); 1 (Totally outpatient,
but with some symptoms); 2 (Requires < 50% of agreed time to rest); 3 (Requires > 50% of agreed time to
rest); 4 (Bedridden). As a criterion for the interpretation of this instrument, we can assume that values lower
than lower than 2 suggest high performance and that equal or greater than two indicates low performance (Ma
et al., 2010; Oken et al., 1982).
Visual Analog Pain Scale
It is a visual analogue scale, which is a 10 cm line, where on the far left is zero (no pain) and on the far right is
10 (the worst pain you could imagine). The patient is instructed to mark where (0 to 10) the pain he is feeling at
the moment would be. The Visual Analog Scale is widely used and considered reliable for the measurement of
acute and cancer-related pain (Bird & Dickson, 2001).
Hospital Anxiety and Depression Scale (HADS)
It is a scale which assesses depressive and anxiety symptoms developed by Zigmond and Snaith (1983) and
later validated for Brazilian Portuguese by Botega, Bio, Zomignani, Garcia, and Pereira (1995), where it presen-
ted internal consistency ranging from 0.68 to 0.77. It is constituted of 14 separate items in depressive symp-
toms of anxiety and has as peculiarity that are considered exclusively psychic symptoms as their constructs.
Anxiety and depression are considered in separate subscales greater than or equal 8 and clinically important
scores of anxiety and depression symptoms are greater than or equal 11 and indicate clinically important levels
of symptoms (Botega, Bio, Zomignani, Garcia, & Pereira, 1995).
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Statistical Analyses
The data were compiled and processed in the statistical software SPSS 17 and the level of significance adop-
ted was 95%.
Results were presented by means of the central tendency (average and median) and variability (standard devi-
ation, range and interquartile range), as well as absolute (n) and relative (%) distributions.
The symmetry of the continuous distributions was evaluated by the Kolmogorov-Smirnov test. The comparison
of the categorical variables between the baseline and follow-up evaluations was performed by the McNemar
test. The Wilcoxon test was used for comparisons between continuous variables, since the data distribution of
the variables involved was characterized as asymmetric.
Results
Considering the results (see Table 2) obtained on the baseline data, it was found that the number of male par-
ticipants, 51.0% (n = 26), was slightly higher.
Table 2
Distribution for Sex, Age, Marital Status, Schooling, Occupation, Religion, Cohabitation, Leisure,
Physical Activity
Characteristic Baseline (n = 51) Follow-up (n = 25)
Sex, n (%)
Male 26 (51.0)
Female 25 (49.0)
Age, M ± SD, Mdn (Range) 60.1 ± 9.3, 59.0 (37 - 83) 61.4 ± 8.1, 61.0 (51 - 86)
Marital Status, n (%)
Single 11 (21.6) 8 (32.0)
Married/Civil Partnership 37 (72.6) 15 (60.0)
Widowed 3 (5.9) 2 (8.0)
Schoolarity, n (%)
Elementary 6 (12.0)
High school 29 (58.0)
College 15 (30.0)
Missing data 1 (2.0)
Occupation, n (%)
Retired 26 (51.0)
Active workers 25 (49.0)
Religion, n (%)
Catholic 30 (58.8)
Protestant 7 (13.7)
Spiritualist 8 (15.7)
Afro Brazilian 2 (3.9)
Atheist 4 (7.8)
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Characteristic Baseline (n = 51) Follow-up (n = 25)
Grouped cohabitation, n (%)
Nobody 6 (11.8)
1 person 12 (23.5)
2 people or more 33 (64.7)
Leisure, n (%)
Yes 44 (86.2)
No 7 (13.7)
Physical Activities (Yes/No), n (%)
No 35 (68.6)
Yes 16 (31.4)
Physical Activities, n (%)
No activity 35 (68.6)
Hiking 14 (27.5)
Streaching 1 (2.0)
Soccer 1 (2.0)
Grouped Frequency, n (%)
Sporadically or once a week 3 (12.5)
3 to 5 times a week 8 (43.8)
Six times a week 5 (6.3)
Note. Percentages (%) are relative to the number of valid cases. For missing data percentages (%) are
relative to the number of all cases.
The average age was estimated at 60.1 (± 9.3) years old, and in the follow-up the estimate was 61.4 (± 8.1)
years old. Marital status was predominant in the baseline, 72.6% (n = 37) as well as in follow-up, 56.0% (n =
14). Also, it was verified in the baseline assessment that the schooling which was most present was high
school, observed in 58.0% (n = 29) of the sample. Regarding the occupation, those who declared themselves
retired made up 51.0% (n = 26) of the sample, remaining 49.0% (n = 25) of active workers. The Catholic reli-
gion was mentioned by 58.8% (n = 30) of the participants.
From data obtained without medical records following a clinical and outcome characterization (Table 3).
The K-RAS gene prevailed in cases where this data was not identified (Table 3), reaching 51.0% (n = 26), how-
ever, it was found that 27,5% (n = 14) were wild classification and 21,5% (n = 11) mutated ones.
The Colon diagnosis was the most observed, representing 66.7% (n = 34) and in what is referred to the time of
diagnosis, the median was 4.2 years (1st-3rd quartile: 3.3-6.7 years), with an average of 5.2 (± 2.5) years.
In relation to staging see Table 3, half of the concentrated sample, without stage IV, 50.0% (n = 25), following
stage III, 34.0% (n = 17) and II, 12.0% (n = 6), was detected as wild-type, 27.5% (n = 14) and mutated, 21.5%
(n = 11). Of the 51 baseline cases, in 26 patients the death was confirmed, and in the remaining 25 investigated
the survival was confirmed (see Table 3).
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Table 3
Distribution for IMC, Death, KRAS, Diagnosis, Diagnostic Time and Staging (N = 51)
Variable Values
IMC (kgm2), M ± SD, Mdn (Range) 25.1 ± 4.4, 23.9 (15.6 – 35.2)
Death, n (%)
Yes 26 (51.0)
No 25 (49.0)
KRAS, n (%)
Mutated 11 (21.5)
Wild 14 (27.5)
Not identified 26 (51.0)
Diagnosis, n (%)
Colon 34 (66.7)
Rectal 17 (33.3)
Time of diagnosis, M ± SD, Mdn (Range) 5.2 ± 2.5, 4.2 (2.4 – 13.7)
Staging, n (%)
II 6 (12.0)
III 17 (34.0)
IV 25 (50.0)
Unknown 2 (4.0)
Missing data 1 (2.0)
Note. Percentages (%) are relative to the number of valid cases. For missing data percentages (%) are
relative to the number of all cases.
Our results regarding the presence of ostomy in the baseline see Table 4, 42.9% (n = 18) of the patients experi-
enced this reality, while in follow-up this proportion was of 19%.
Regarding the treatment see Table 4, information was observed only at follow-up. In the chemotherapy proto-
cols, the most observed baseline chemotherapy were FOLFOX, 33.3% (n = 17), FOLFIRI, 23.5% (n = 12), and
FOLFIRI + Cetuximab, 17.7% (n = 9). Regarding the treatment see Table 4, information was observed on base-
line and follow-up. In the chemotherapy protocols, the most observed baseline chemotherapy were FOLFOX,
33.3% (n = 17), FOLFIRI, 23.5% (n = 12), and FOLFIRI + Cetuximab, 17.7% (n = 9). The chemotherapy proto-
cols were confirmed in 23.3% (n = 7) of the sample in the follow-up.
In the follow-up assessment, of the six cases with valid answers, in four (66.7%) FOLFIRI was used. When
asked about a presence of pain, it was confirmed in 21.6% (n = 11) at baseline and 26.1% (n = 6) within follow-
up.
Regarding the reported cases see Table 4, the baseline for the median for pain intensity of 3.0 points with an
average of 3.5 (± 2.1), whereas, to accompany a median was 5.5 with an average of 5.7 (± 2.3) points.
Considering the ECOG symptom scale Table 4, predominant in the sample was "Normal activity", with propor-
tions of 84.3% (n = 43) at baseline and 87.0% (n = 20) at follow-up. Regarding the anxiety and depression pit-
falls, information collected during the follow-up, a median was 4.0 points with an average of 4.4 (± 3.1) points
and 2.0 points with an average of 3, 5 (± 3.6) points, respectively.
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Table 4
Absolute and Relative Distribution for Ostomy, Treatment, Antineoplastic Drug, Visual Analog Scale, ECOG, Anxiety and Depression Core
in Both Moments of Evaluation
Variable T1 (n = 51) Basal
Paired assessments
pT1 (n = 25) T2 (n = 25) follow up
Ostomy, n (%) 0.011
Yes 18 (42.9) 11 (50.0) 4 (19.0)
No 24 (57.2) 11 (50.0) 17 (81.0)
Missing data, n (%) 9 (17.6) 3 (12.0) 4 (16.0)
Treatment, n (%) 0.009
Yes 51 (100.0) 25 (100.0) 7 (28.0)
No 0 (0.0) 18 (72.0)
Chemotherapy drug, n (%) —
5-Fu+Folinic Acid 5 (9.8) 5 (20.0)
FOLFOX 17 (33.3) 10 (40.0)
FOLFIRI 12 (23.5) 3 (12.0) 4 (66.7)
FOLFIRI + Cetuximab 9 (17.7) 2 (8.0)
FOLFOX + Bevacizumab 3 (5.9) 2 (8.0) 2 (33.3)
FOLFIRI + Bevacizumab 4 (7.8) 2 (8.0)
Mitomicyn+ 5-Fu 1 (2.0) 1 (4.0)
Missing data, n (%) 19 (76.0)
Pain Presence (EVA), n (%) 0.788
No 40 (78.4) 21 (84.0) 17 (73.9)
Yes 11 (21.6) 4 (16.0) 6 (26.1)
Missing data, n (%) 2 (8.0)
Visual Analog Scale (Pain)*, M ± SD, Mdn (Range) 3.5 ± 2.1, 3.0 (1.0 – 7.0) 4.2 ± 2.2, 5.0 (2.0 – 5.7) 5.7 ± 2.3, 5.5 (3.0 – 8.0) 0.123
ECOG – symptomatic scale, n (%) —
Normal activity 43 (84.3) 20 (87.0) 20 (87.0)
Symptomatic but outpatient 6 (11.8) 1 (4.0) 1 (4.3)
Bedridden more than 50% of the time 2 (3.9) 0 (0.0)
Bedridden less than 50% of the time 0 (0.0) 2 (8.0) 2 (8.7)
Missing data, n (%) 2 (8.0) 2 (8.0)
Score A (anxiety)a, M ± SD, Mdn (Q1-Q3) 4.4 ± 3.1, 4.0 (0.0 – 11.0) —
Anxiety – classification, n (%) —
Normal (up to 7) 18 (78.3)
With anxiety (mild or moderate) 5 (21.7)
Missing data, n(%) 2  (8.0)
Score D (Depression)a, M ± SD, Mdn (Q1-Q3) 3.5 ± 3.6, 2.0 (0.0 – 12.0) —
Depression – classification, n (%) —
Normal (up to 7) 19 (82.6)
With depression mild (mild or moderate) 4 (17.3)
Missing data, n (%) 2 (8.0)
Note. Percentages (%) are relative to the number of valid cases. For missing data percentages (%) are relative to the number of all cases.
aDepression and anxiety scores were assessed only at follow-up.
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As for a scale for anxiety and depression, predominant in the two characteristics of a normal classification: de-
pression: 82.6% (n = 19) and anxiety, 78.3% (n = 18).
Considering the analysis of the variables from Table 5 on the cases which in T1 that were present at the follow
up (T2), it was verified that in Ostomy there was a significant reduction (p = 0.011) in the number of cases with
this characteristic in T2, 19.0% (n = 4) compared to T1, 50.0% (n = 11).
At the time of treatment, all 25 patients were confirmed in T1, but in T2 this number changed to seven (28.0%),
that is, there was a significant reduction (p = 0.009) in the number of patients in T2 treatment. The presence of
pain in T1 was confirmed by 16.0% (n = 4) of patients, while in T2 there was a slight increase, 26.1% (n = 6) (p
= 0.788). Other comparisons of the paired data, based on the cases that reached the follow-up, were not repre-
sentative, as shown in Table 5.
Table 5
Mean, Standard Deviation and Median for QLQ C-30
Quality of Life – QLQ C30
T1 (N = 51)
Paired assessmentsa
p
T1 (n = 23) T2 (n = 23)
M SD Mdn M SD Mdn M SD Mdn
Average global health / Quality of Life (29 and 30) 76.6 17.0 75.0 80.1 16.0 75.0 86.2 13.9 83.3 0.108
Functional Scale
Physical functioning (1 to 5) 80.9 23.1 93.3 79.7 24.9 93.3 87.2 16.8 93.3 0.195
Role Functioning (6 and 7) 81.7 23.6 83.3 81.2 18.3 83.3 85.5 27.2 100.0 0.520
Emotional functioning (21 to 24) 72.9 21.9 75.0 70.3 22.3 66.7 74.5 29.4 83.3 0.468
Cognitive Functioning (20 to 25) 82.4 23.4 100.0 80.4 23.9 83.3 84.1 26.3 100.0 0.496
Social Functioning (26 and 27) 72.6 26.6 66.7 71.0 24.7 66.7 86.2 26.4 100.0 0.031
Symptoms Scale
Fadiga (10, 12 and 18) 25.0 23.6 22.2 29.5 25.0 22.2 20.3 25.4 11.1 0.193
Nausea / vomit (14 and 15) 14.4 20.6 0.0 17.4 21.0 16.7 8.0 15.0 0.0 0.056
Pain (9 and 19) 11.8 22.9 0.0 12.3 25.7 0.0 18.8 33.8 0.0 0.329
Dyspnea (8) 8.5 18.7 0.0 10.1 23.4 0.0 2.9 9.6 0.0 0.057
Insomnia (11) 25.5 30.3 0.0 31.9 31.0 33.3 18.8 31.5 0.0 0.083
Loss of appetite (13) 20.3 28.3 0.0 21.7 29.5 0.0 2.9 13.9 0.0 0.009
Constipation (16) 24.8 31.9 0.0 20.3 29.7 0.0 13.0 26.1 0.0 0.381
Diarrhea (17) 18.3 25.2 0.0 14.5 19.7 0.0 8.7 23.0 0.0 0.329
Financial Struggle (28) 20.9 32.6 0.0 21.7 31.2 0.0 11.6 25.8 0.0 0.245
aWilcoxon test.
In the baseline Quality of Life results (Table 5), it was found that the average score for general quality of life
was 76.6 ± 17.0 (p = 0.108), an estimate that reference values for this population (60.7 ± 23.4).
In the evaluation of the performance subscales that make up the instrument, the highest score occurred in the
cognitive performance subscale (82.4 ± 23.4; median: 100.0), while the lowest average was identified in the
emotional performance subscale (72.9 ± 21.9, median: 75.0), these results, according to the reference values
of the instrument for this clinical population. On the results of the symptom scale, the average scores indicated
a higher impairment of quality of life (greater symptomatology) in the subscales of insomnia (25.5 ± 30.3, me-
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dian: 0.0), fatigue (25.0 ± 23, 6; median: 0.0) and constipation (24.8 ± 31.9; median: 0.0), these results were
consistent with EOTRC reference values for this condition.
Based on the data obtained in follow-up, these were paired and compared to those observed at the baseline
and, according to the results presented in Table 5, for the overall quality of life score, it is observed that the
average in the follow-up (86.2 ± 13.9; median: 83.3) was higher than in the baseline (80.1 ± 16.0; median:
75.0). However, the difference observed was not significant (p = 0.108) but it appears that a tendency.
In the performance subscale, the significant difference was attributed to the social performance subscale (p =
0.031), indicating that the average follow-up score (86.2 ± 26.6; median: 100.0) was significantly higher than
baseline (71.1 ± 24.7, median: 66.7), that is, in the follow-up there was an improvement in the quality of life of
the investigated patients.
Regarding the other performance subscales, although the average scores were higher at follow-up, the differ-
ences were not significant when compared to the baseline means.
Concerning the subscales of symptoms, a significant difference in loss of appetite was detected (p = 0.009)
where the average score was significantly lower at follow-up (2.9 ± 13.9; median: 0.0) when compared to the
baseline (21.7 ± 29.5; median: 0.0). That is, the paired investigators presented a lower impairment of this symp-
tom at follow-up. In the other subscales of the symptomatology, the average score was lower at follow-up, how-
ever, the observed differences between baseline and follow-up were not significant.
Concerning the subscales of symptoms, a significant difference in loss of appetite was detected (p = 0.009),
where the average score was significantly lower at follow-up (2.9 ± 13.9; median: 0.0) when compared to the
baseline (21.7 ± 29.5, median: 0.0). That is, the paired investigators presented a lower impairment of this symp-
tom at follow-up.
In the other subscales of the symptomatology, the average score was lower at follow-up, however, the ob-
served differences between baseline and follow-up were not significant.
It should be noted that, in the subscales, nausea / vomiting and dyspnea, borderline significance was observed
(0.05 < p < 0.10), suggesting that the average follow-up score may be lower, indicating a tendency the sympto-
matology may be lower in this evaluation compared to the baseline.
In the financial difficulty subscale, the observed differences between the average scores were not significant in
this sample.
Conclusions
In the present study, patients with diagnosis and treatment for colorectal cancer were evaluated over time, and
this allowed us to characterize the population in order to allow the recognition of possible factors that may influ-
ence Quality of Life. Both physical and psychosocial aspects have proved to be representative of a possible
reality because indicates tendency. As this clinical population performed better than the C-30 reference values
presented by EORTC, it is understood that these higher scores portray characteristics of private health care,
which has multiprofessional care, without burden to the patient (Scott et al., 2008).
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Over time, the social function improved significantly, accompanied by an improvement in the quality of life of
these patients. This can be attributed to factors such as adaptation processes and resilience that may be acting
moderating or mediating favouring Quality of Life and its domains, corroborating studies that indicate that the
age factor favours adaptation and resilience in patients (Cohen, Baziliansky, & Beny, 2014).
The follow-up scores of the subjects (n = 6) showed that the subjects achieved significant Quality of Life-related
improvements in social constructs, nausea, dyspnea, insomnia, loss of appetite, improved over time, but the
improvements identified only refer to these six people. This finding corroborates the studies with survivors of
colorectal cancer although, in contrast to not showing risk factors for poor Quality of Life such as: advanced
stage of disease, presence of ostomy, rectal cancer, fatigue, smoking, being single, concerning ostomized pa-
tients, the presence of ostomy in the follow-up was reduced to only four subjects who did not show to be nega-
tively impacting their Quality of Life, since there were no significant losses in Quality of Life (Chambers et al.,
2012).
However, when we compared the baseline (n = 18) ostomized patients presented better cognitive performance,
less pain and less constipation, besides other symptoms and performances in subscales which were not statis-
tically expressive, but which suggest that depending on the ostomy, possibly the care is greater with symptoma-
tological issues, which establishes contradiction with equivalent studies (Grant et al., 2011; Nicolussi & Sawa-
da, 2009).
Considering that in the study population it was not possible to verify that ostomy implies impairment of quality of
life at both the baseline and follow-up (despite the suggestion to the contrary), the methodological limitation is
pointed out because the confrontation can not be performed with the time of ostomization. This may have com-
promised the strength of the analyses and their explanatory power. However, these findings are supported by
the evidence that adaptation occurs in two years in ostomy patients (Salles, Becker, & Faria, 2014).
However, although quality of life is generally good, as indicated by a systematic review with survivors of color-
ectal cancer, it indicates that they have specific physical and psychological problems. Thus, studies suggest
that Quality of Life may serve to identify survivors with special needs, but considers that further studies focused
on these problems are necessary (Jansen, Koch, Brenner, & Arndt, 2010).
The present study presented as limitations the sample loss resulting from the characteristic of the population
constituted, in the majority, by patients with unfavorable prognoses. In addition the study shows limitations due
to the no parametric tests used to analyze the data. New studies with a larger number of participants are nee-
ded to characterize the specificities of patients with Colorectal Cancer in the population of southern Brazil, con-
sidering different perspectives of cancer care, both in the public and private health systems.
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